Evaluation of the Relationship Between IL-6 Gene Single Nucleotide Polymorphisms and the Severity of COVID-19 in an Iranian Population

Overview

Journal Cytokine

Specialties Allergy & Immunology
Biology

Date 2022 Apr 23

PMID 35461173

Authors

Sara Falahi

Mohammad Hossein Zamanian

Parisa Feizollahi

Alireza Rezaiemanesh

Farhad Salari

Zahra Mahmoudi

Ali Gorgin Karaji

Affiliations

Soon will be listed here.

Abstract

Background: Emerged coronavirus disease 2019 (COVID-19) is a pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2). Disease severity is associated with elevated levels of proinflammatory cytokines, such as interleukin-6 (IL-6). Genetic polymorphisms in the regulatory regions of cytokine genes may be associated with differential cytokine production in COVID-19 patients. This study aimed to investigate the association between three potentially functional single-nucleotide polymorphisms (SNPs) in the promoter region of IL-6 and the severity of susceptibility to COVID-19 in an Iranian population.

Methods: In total, 346 individuals (175 patients with severe COVID-19 and 171 patients with mild COVID-19) were recruited for this cohort study. Genomic DNA was extracted from peripheral blood leukocytes of patients to determine the genotypes of three selected SNPs (rs1800795 (-174 G > C), rs1800796 (-572 G > C), and rs1800797 (-597 G > A)) in the promoter region of the IL-6 gene using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method.

Results: There were no significant differences in the genotype or allele distribution of selected SNPs (rs1800795 (-174 G > C), rs1800796 (-572 G > C), and rs1800797 (-597 G > A)) in the promoter region of the IL-6 gene in patients with severe COVID-19 and patients with mild COVID-19.

Discussion: Our study indicated that these SNPs are not associated with COVID-19 severity in the Kurdish population from Kermanshah, Iran.

Citing Articles

Toll-like receptors polymorphisms and COVID-19: a systematic review.

Dos Santos B, Dos Santos L, Ferreira J, Dos Santos A, Sortica V, de Souza Figueiredo E Mol Cell Biochem. 2024; .

PMID: 39520513 DOI: 10.1007/s11010-024-05137-3.

Role of interleukin 6 polymorphism and inflammatory markers in outcome of pediatric Covid- 19 patients.

AbdelAziz R, Abd-Allah S, Moness H, Anwar A, Mohamed Z BMC Pediatr. 2024; 24(1):625.

PMID: 39354444 PMC: 11443869. DOI: 10.1186/s12887-024-05071-9.

Genetic, Clinical, Epidemiological, and Immunological Profiling of IgG Response Duration after SARS-CoV-2 Infection.

da Costa F, de Sarges K, da Silva R, Dos Santos E, Nascimento M, Rodrigues A Int J Mol Sci. 2024; 25(16).

PMID: 39201427 PMC: 11354850. DOI: 10.3390/ijms25168740.

Pathway-Based Mendelian Randomization for Pre-Infection IL-6 Levels Highlights Its Role in Coronavirus Disease.

Kamali Z, Esmaeil N, Thio C, Vaez A, Snieder H Genes (Basel). 2024; 15(7).

PMID: 39062668 PMC: 11275426. DOI: 10.3390/genes15070889.

The Interleukin-6 gene variants may protect against SARS-CoV-2 infection and the severity of COVID-19: a case-control study in a Moroccan population.

Noureddine R, Baba H, Aqillouch S, Abounouh K, Laazaazia O, Elmessaoudi-Idrissi M BMC Med Genomics. 2024; 17(1):139.

PMID: 38783290 PMC: 11112821. DOI: 10.1186/s12920-024-01911-w.

References

Kirtipal N, Thakur H, Sobti R, Janmeja A . Association between gene polymorphism and the risk of chronic obstructive pulmonary disease in the north Indian population. Mol Biol Res Commun. 2020; 9(2):41-43. PMC: 7382402. DOI: 10.22099/mbrc.2019.34594.1431. View

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054-1062. PMC: 7270627. DOI: 10.1016/S0140-6736(20)30566-3. View

Tanaka T, Narazaki M, Kishimoto T . IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014; 6(10):a016295. PMC: 4176007. DOI: 10.1101/cshperspect.a016295. View

Liu X, Wang H, Shi S, Xiao J . Association between IL-6 and severe disease and mortality in COVID-19 disease: a systematic review and meta-analysis. Postgrad Med J. 2023; 98(1165):871-879. DOI: 10.1136/postgradmedj-2021-139939. View

Levi M, van der Poll T, ten Cate H, van Deventer S . The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia. Eur J Clin Invest. 1997; 27(1):3-9. DOI: 10.1046/j.1365-2362.1997.570614.x. View

Gong J, Dong H, Xia Q, Huang Z, Wang D, Zhao Y . Correlation analysis between disease severity and inflammation-related parameters in patients with COVID-19: a retrospective study. BMC Infect Dis. 2020; 20(1):963. PMC: 7750784. DOI: 10.1186/s12879-020-05681-5. View

Abbasifard M, Khorramdelazad H . The bio-mission of interleukin-6 in the pathogenesis of COVID-19: A brief look at potential therapeutic tactics. Life Sci. 2020; 257:118097. PMC: 7361088. DOI: 10.1016/j.lfs.2020.118097. View

Saxena R, Chawla Y, Verma I, Kaur J . IL-6(-572/-597) polymorphism and expression in HBV disease chronicity in an Indian population. Am J Hum Biol. 2014; 26(4):549-55. DOI: 10.1002/ajhb.22562. View

Du F, Liu B, Zhang S . COVID-19: the role of excessive cytokine release and potential ACE2 down-regulation in promoting hypercoagulable state associated with severe illness. J Thromb Thrombolysis. 2020; 51(2):313-329. PMC: 7365308. DOI: 10.1007/s11239-020-02224-2. View

10.

Gupta K, Khan M, Singh S . Constitutive Inflammatory Cytokine Storm: A Major Threat to Human Health. J Interferon Cytokine Res. 2019; 40(1):19-23. DOI: 10.1089/jir.2019.0085. View

11.

Giamarellos-Bourboulis E, Netea M, Rovina N, Akinosoglou K, Antoniadou A, Antonakos N . Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. Cell Host Microbe. 2020; 27(6):992-1000.e3. PMC: 7172841. DOI: 10.1016/j.chom.2020.04.009. View

12.

Bhaskar S, Sinha A, Banach M, Mittoo S, Weissert R, Kass J . Cytokine Storm in COVID-19-Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper. Front Immunol. 2020; 11:1648. PMC: 7365905. DOI: 10.3389/fimmu.2020.01648. View

13.

Wu Z, McGoogan J . Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13):1239-1242. DOI: 10.1001/jama.2020.2648. View

14.

Aleagha O, Oltulu P, Sadeghi M . Association between interleukin 6 polymorphisms (rs1800796, rs1800795, rs2069837, rs17147230, and rs1800797) and hepatocellular carcinoma susceptibility: a meta-analysis. Clin Exp Hepatol. 2021; 6(4):359-366. PMC: 7816640. DOI: 10.5114/ceh.2020.102171. View

15.

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

16.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

17.

Kerget F, Kerget B . Frequency of Interleukin-6 rs1800795 (-174G/C) and rs1800797 (-597G/A) Polymorphisms in COVID-19 Patients in Turkey Who Develop Macrophage Activation Syndrome. Jpn J Infect Dis. 2021; 74(6):543-548. DOI: 10.7883/yoken.JJID.2021.046. View

18.

Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L . Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia. J Infect Dis. 2020; 221(11):1762-1769. PMC: 7184346. DOI: 10.1093/infdis/jiaa150. View

19.

Vitkauskaite A, Celiesiute J, Juseviciute V, Jariene K, Skrodeniene E, Samuolyte G . IL-6 597A/G (rs1800797) and 174G/C (rs1800795) Gene Polymorphisms in the Development of Cervical Cancer in Lithuanian Women. Medicina (Kaunas). 2021; 57(10). PMC: 8538235. DOI: 10.3390/medicina57101025. View

20.

Bogdanovic Z, Marinovic-Terzic I, Kuret S, Jeroncic A, Bradaric N, Forempoher G . The impact of IL-6 and IL-28B gene polymorphisms on treatment outcome of chronic hepatitis C infection among intravenous drug users in Croatia. PeerJ. 2016; 4:e2576. PMC: 5088582. DOI: 10.7717/peerj.2576. View